The characterization of CRS-endotypes focusses on the inflammatory disease mechanisms. Special endotypes allow for treatment with specific monoclonal antibodies (biologicals).  Until now, no internationally accepted endotype definition exists for CRS/CRSwNP. This TF will focuss on the characterization of CRS-endotypes and the definition of diagnostic measures or biomarkers for routine treatment and for scientific studies and thus to help identifying patient groups that will benefit most from new personalized therapies.

ENT Section

Chair: Sanna Toppila Salmi
Secretary: Valérie Hox